View More Recent Stories

Feb 12, 2025 07:17AM Anaptysbio (ANAB) Halted, News Pending Ahead of Top-line Data from Phase 2b Trial of Rosnilimab
Feb 4, 2025 06:40AM H.C. Wainwright Reiterates Neutral Rating on AnaptysBio (ANAB)
Feb 3, 2025 07:30AM Vanda Pharmaceuticals (VNDA) and Anaptys (ANAB) Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab
Jan 6, 2025 10:35AM TD Cowen: '10 Potential "Thome Run" Catalysts to Watch in 2025'
Jan 3, 2025 08:23AM Piper Sandler Explores Direct and Indirect Catalysts for Selected Biotechnology Companies
Dec 20, 2024 10:26AM Increasing unusual option volume: QUBT CE GALT TSEM ICLN ANAB MVST BBD KULR FREY RGTI OLN NTR
Dec 18, 2024 10:06AM AnaptysBio (ANAB) PT Lowered to $20 at Truist Securities
Dec 12, 2024 07:18AM AnaptysBio (ANAB) PT Lowered to $36 at Guggenheim
Dec 12, 2024 05:59AM Increasing unusual option volume: ANAB RGTI CADL QUBT GLBE SFIX OLLI AON
Dec 11, 2024 08:31AM Anaptysbio (ANAB) Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis
Dec 11, 2024 08:26AM Anaptysbio (ANAB) Halted, News Pending
Dec 2, 2024 06:08AM BTIG Downgrades AnaptysBio (ANAB) to Neutral
Nov 19, 2024 02:45PM Truist Securities Reiterates Hold Rating on AnaptysBio (ANAB)
Nov 7, 2024 06:13AM Guggenheim Reiterates Buy Rating on AnaptysBio (ANAB)
Nov 6, 2024 06:12AM AnaptysBio (ANAB) PT Lowered to $52 at H.C. Wainwright
Nov 6, 2024 05:58AM AnaptysBio (ANAB) PT Lowered to $45 at Leerink Partners
Nov 5, 2024 04:58PM AnaptysBio, Inc. (ANAB) Tops Q3 EPS by 56c
Nov 5, 2024 04:30PM Anaptysbio (ANAB) Files $500M Mixed Shelf
Oct 24, 2024 01:54PM Anaptysbio (ANAB) spreaders of 917 contracts of November 40 calls against 917 contracts of April 50 calls
Oct 21, 2024 06:13AM AnaptysBio (ANAB) PT Raised to $90 at Guggenheim
Oct 15, 2024 07:25AM Piper Sandler Reiterates Overweight Rating on AnaptysBio (ANAB)
Oct 3, 2024 08:19AM Leerink Partners Reiterates Outperform Rating on AnaptysBio (ANAB)
Oct 2, 2024 07:45AM Piper Sandler Reiterates Overweight Rating on AnaptysBio (ANAB)
Sep 7, 2024 08:00PM Here's the list of biotech stocks that have key data catalysts in 2025
Sep 5, 2024 05:15AM BTIG Reiterates Buy Rating on Anaptysbio (ANAB) (correction)
Aug 19, 2024 06:14AM Guggenheim Reiterates Buy Rating on AnaptysBio (ANAB)
Aug 15, 2024 08:18AM AnaptysBio (ANAB) PT Raised to $30 at Truist Securities
Aug 14, 2024 06:14AM Anaptysbio (ANAB) Prices 2.75M Share Offering at $36.50/sh
Aug 6, 2024 09:23AM TD Cowen Reiterates Buy Rating on AnaptysBio (ANAB)
Aug 6, 2024 04:00AM AnaptysBio, Inc. (ANAB) Misses Q2 EPS by 67c
Jul 19, 2024 02:20AM JPMorgan Upgrades AnaptysBio (ANAB) to Overweight
Jun 21, 2024 05:30AM TD Cowen Reiterates Buy Rating on AnaptysBio (ANAB)
Feb 16, 2024 12:00PM Piper Sandler sees a potential 250% upside in this biotech stock
View More Recent Stories